Regencell Bioscience Holdings Ltd
RGC
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.79B
Close$
$0.00
99.9% downside
Current Fair Value
99.9% downsideOvervalued by 99.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.79 Billion |
|---|---|
| Enterprise Value | $2.79 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.01 |
| Beta | 1.43 |
| Outstanding Shares | 494,488,908 |
Return
| Return on Equity | -913.36% |
|---|---|
| Return on Assets | -369.60% |
| Return on Invested Capital | -842.23% |
Valuation & Multiples
| P/E Ratio | -397.18 |
|---|---|
| PEG | -212.51 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -246.05 |
| Enterprise Value to Net Income | -251 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.32 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
June 15, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
October 28, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 4.0803▲ 230.82% |
|---|---|
| Total Calls | 46,100▼ 23.29% |
| Total Puts | 188,100▲ 76.62% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.28%▲ 0.15% |
|---|---|
| Total Invested | $8.56M▼ 48.02% |
| Investors Holding | 41▲ 4.00% |
ESG Score
No data